Prevalence-Based Economic Evaluation

Value in Health

Volumn 1, Issue 4, 1998, Pages 251-259

  Mauskopf, Josephine ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0007699244     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.1998.140251.x     Document Type: Article

References (32)

1. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
2. Sloan F, Conover C. The use of cost-effectiveness/cost-benefit analysis in actual decision-making: current status and prospects. In: Sloan F, ed. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies. Cambridge University Press, 1995:207-32.
3. Davies L, Coyle D, Drummond M, et al. Current status of economic appraisal of health technology in the European Community: report of the network. Soc Sci Med 1994;38:1601-7.
4. Foundation Health Integrated Pharmaceutical Services. Guidelines for Formulary Submissions. Rancho Cordova, CA: Foundation HealthCorporation, 1996.
5. Gold M, Siegel J, Russell L, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford UniversityPress, 1996.
6. Hartunian N, Smart C, Thompson M. The Incidence and Economic Costs of Major Health Impairments. Lexington, MA: Lexington Books, DC Heath andCompany, 1981.
7. Cooper B, Rice D. The economic cost of illness revisited. Social Security Bull 1976;39:21-36.
8. Mauskopf J, Simpson K. The cost and benefits of alternative drug treatment regimens for HIV patients. Poster presented at the Third Conference on Retroviruses and Opportunistic Infections, Washington DC, January 28-February 1, 1996.
9. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes (2nd ed). New York: Oxford University Press, 1997.
10. Bootman L, Townsend R, McGrath W. Principles of Pharmacoeconomics (2nd ed). Cincinnati: Harvey Whitney BooksCompany, 1996.
11. Mauskopf J, Paul J, Grant D, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. PharmacoEconomics 1998;13:277-88.
12. Kjekshus J, Pedersen T. Reducing the risk of coronary events: evidence from the Scandinavian Sim- vastatin Survival Study (4S). Am J Cardiol 1995;76:64C-68C.
13. Mauskopf J, Backhouse M, Jones D, et al. Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: impact on hospital resource use and charges. J Pediatr 1995;126:94-101.
14. Backhouse ME, Mauskopf JA, Jones D, et al. Economic outcomes of synthetic surfactant rescue therapy in infants weighing 1250 g or more with respiratory stress syndrome: results from a randomized trial. PharmacoEconomics 1994;6:358-69.
15. Mark D, Hlatky M, Califf R, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
16. Schwartz R, Luby A, Scanlon J, et al. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500-1500 grams. N Engl J Med 1994;330:1476-80.
17. Crown W, Hylan T, Meneades L. Antidepressant selection and use and healthcare expenditures: an empirical approach. PharmacoEconomics 1998;13:435-48.
18. Siegel R, Halpern N, Almenoff P, et al. A prospective randomized study of impatient IV antibiotics for community-acquired pneumonia: the optimal duration of therapy. Chest 1996;110:965-71.
19. Hendrickson J, North D. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriazone to oral cefpodoxime proxetil. Ann Pharmacother 1995;29: 561-5.
20. Oddone E, Cowper P, Hamilton J, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ 1993;307:1322-5.
21. Schulman K, Lynn L, Glick H, et al. Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection. Ann Intern Med 1991;114:798-802.
22. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost-effectiveness of lamivudine zidovu- dine combination therapy in HIV infection. PharmacoEconomics 1997;12(1):54-66.
23. Moore R, Bartlett J. Combination antiretroviral therapy in HIV infection: an economic perspective. PharmacoEconomics 1996;10:109-13.
24. Mauskopf J, Lacey L, Kempel A, Simpson K. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Managed Care 1998. (In press.)
25. Simpson K, Hatziandreu E, Andersson F, et al. Cost-effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/ul in 5 European countries. PharmacoEconomics 1994;6:553-62.
26. Paltiel A, Scharfstein J, Seage G, et al. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection. Med Decis Making 1998;18:S93-105.
27. Toison J, Mauskopf J, Albright J, et al. Validation of the Ryan White Title II ADAP budget model. Poster presented at the Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28-October 1, 1997.
28. Jefferson T, DeMicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 1994;3:25-37.
29. Hamilton J. Hepatitis B virus vaccine: an analysis of its potential use in medical workers. JAMA 1983;250:2145-50.
30. Lieu T, Cochi S, Black S, et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:375-81.
31. Cook J, Dasbach E, Coplan P, et al. Using HIV viral RNA to estimate the cost-effectiveness of indinavir alone and in combination. Poster presented at the Fourth Conference on Retroviruses and Opportunistic Infections, Washington DC, January 22-26, 1997.
32. Moore R, Hidalgo J, Bareta J, et al. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7:349-54.